bioAffinity Technologies annual depreciation and amortization
2021
2022
2023
2024
2025
bioAffinity Technologies Depreciation & Amortization Growth & History (BIAF)
bioAffinity Technologies's depreciation and amortization was $504,836 for fiscal 2025.
View full bioAffinity Technologies company overviewbioAffinity Technologies annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $504,836 | −$100,801 | −16.64% |
| 2024 | 2024-12-31 | $605,637 | $356,045 | +142.65% |
| 2023 | 2023-12-31 | $249,592 | $239,410 | +2351.31% |
| 2022 | 2022-12-31 | $10,182 | $5,365 | +111.38% |
| 2021 | 2021-12-31 | $4,817 | — | — |
bioAffinity Technologies quarterly depreciation and amortization
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $61,556 | −$51,673 | −45.64% |
| Q1 2026 | 2026-03-31 | $114,518 | −$40,070 | −25.92% |
| Q4 2025 | 2025-12-31 | $123,659 | — | — |
| Q3 2025 | 2025-09-30 | $113,360 | −$37,938 | −25.08% |
| Q2 2025 | 2025-06-30 | $113,229 | −$37,841 | −25.05% |
| Q1 2025 | 2025-03-31 | $154,588 | $4,951 | +3.31% |
| Q3 2024 | 2024-09-30 | $151,298 | $93,729 | +162.81% |
| Q2 2024 | 2024-06-30 | $151,070 | $129,518 | +600.96% |
| Q1 2024 | 2024-03-31 | $149,637 | $127,953 | +590.08% |
| Q3 2023 | 2023-09-30 | $57,569 | $56,796 | +7347.48% |
| Q2 2023 | 2023-06-30 | $21,552 | $20,512 | +1972.31% |
| Q1 2023 | 2023-03-31 | $21,684 | $20,645 | +1987.01% |
| Q3 2022 | 2022-09-30 | $773 | −$427 | −35.58% |
| Q2 2022 | 2022-06-30 | $1,040 | — | — |
| Q1 2022 | 2022-03-31 | $1,039 | — | — |
| Q3 2021 | 2021-09-30 | $1,200 | — | — |
bioAffinity Technologies depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, bioAffinity Technologies's depreciation and amortization increased from $4,817 to $504,836, a change of $500,019. The latest reported quarter, Q2 2026, shows $61,556.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review bioAffinity Technologies source filings ↗